<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04888754</url>
  </required_header>
  <id_info>
    <org_study_id>NL72765.078.20</org_study_id>
    <nct_id>NCT04888754</nct_id>
  </id_info>
  <brief_title>A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands</brief_title>
  <acronym>CHRONO</acronym>
  <official_title>A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands: The CHRONO Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective non-interventional cohort study at Erasmus MC of adult chronic HIV infected&#xD;
      patients of ≥18 years of age who initiate antiretroviral therapy in routine care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV cannot be cured with the current treatment armamentarium. A reservoir of latently HIV&#xD;
      infected long lived CD4+T-cells is present in patients with HIV that are not affected by&#xD;
      antiretroviral therapy. The evolution of this reservoir after therapy initiation is ill&#xD;
      understood, as are the potential strategies to eradicate this reservoir. This study aims to&#xD;
      anticipate on future HIV cure strategies by building a cohort to study ex vivo the reservoirs&#xD;
      of HIV patients, the obstacles to cure HIV, and new therapeutic compounds and strategies.&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
        1. Change in viral reservoir size after antiretroviral treatment initiation.&#xD;
&#xD;
        2. Evolution of phenotypical and functional aspects of the anti-HIV host immune responses.&#xD;
&#xD;
        3. Ex vivo activity of established and novel HIV latency reversing agents.&#xD;
&#xD;
        4. Variance in HIV reservoir and host immunity between HIV subtypes and clinical variables.&#xD;
&#xD;
      A project from the Erasmus MC HIV Eradication Group (EHEG).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">January 2034</completion_date>
  <primary_completion_date type="Anticipated">January 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To develop a prospective cohort in the Netherlands of chronic HIV infected patients within-depth reservoir characterization for future cure interventions.</measure>
    <time_frame>5-10 years</time_frame>
    <description>The HIV latent reservoir will be characterised in chronic HIV patients using novel techniques like FISH-flow</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To study the evolution of the HIV reservoir and immune host responses over time during antiretroviral therapy.</measure>
    <time_frame>5-10 years</time_frame>
    <description>The HIV reservoir will be characterised over time to study the dynamics of the reservoir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To explore established and putative new interventions aimed at curing HIV.</measure>
    <time_frame>5-10 years</time_frame>
    <description>Blood and leucapheresis samples will be collected for testing of HIV cure drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore differences in reservoir size, activity and host responses, and their relation with clinical characteristics, between patients with different dominant HIV subtypes and sexes.</measure>
    <time_frame>5-10 years</time_frame>
    <description>Blood and leucapheresis samples will be collected for reservoir characterisation to compare reservoirs between patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare and validate new reservoir assays with current established assays.</measure>
    <time_frame>5-10 years</time_frame>
    <description>Blood and leucapheresis samples will be collected to compare and validate new reservoir assays</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV Infections</condition>
  <condition>HIV-1-infection</condition>
  <condition>HIV-2 Infection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples and leucapheresis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are 18 years or older with a confirmed HIV infection without prior exposure to&#xD;
        cART (treatment naïve). Prior use of pre-exposure prophylaxis is allowed.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years.&#xD;
&#xD;
          -  Confirmed HIV-1 or HIV-2 infection&#xD;
&#xD;
          -  Judged willing to initiate and adhere to cART by the HIV physician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to place venous catheters to draw blood.&#xD;
&#xD;
          -  Major comorbidities:&#xD;
&#xD;
               1. Severe symptomatic anemia or recent symptomatic cardiovascular event (un-stable&#xD;
                  angina pectoris, decompensated heart failure, myocardial infarction).&#xD;
&#xD;
               2. The inability to participate due to any other relevant social,&#xD;
                  environmental,psychological, factors or according to the HIV treating physician's&#xD;
                  judgement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Casper Rokx, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tokameh Mahmoudi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Casper Rokx, MD PhD</last_name>
    <phone>0681336328</phone>
    <email>c.rokx@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tokameh Mahmoudi, PhD</last_name>
    <email>t.mahmoudi@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casper Rokx, MD PhD</last_name>
      <phone>+31681336328</phone>
      <email>c.rokx@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Jeroen van Kampen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvonne Muller, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tokameh Mahmoudi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Boucher, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Burger, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rob Gruters, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathryn Hensley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Katsikis, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Casper Rokx</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HIV cure</keyword>
  <keyword>HIV reservoir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>No definitive decision on this yet. This will also depend on confidentiality.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

